Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

CONTEXT: No head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium–glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D). OBJECTIVE: We indirectly compared the efficacy of OW semaglutide 1 mg vs once-daily...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Endocrinol Metab
Huvudupphovsmän: Lingvay, Ildiko, Capehorn, Matthew S, Catarig, Andrei-Mircea, Johansen, Pierre, Lawson, Jack, Sandberg, Anna, Shaw, Robert, Paine, Abby
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Clinical Research Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549924/
https://ncbi.nlm.nih.gov/pubmed/32827435
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa577
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk